FDA approves first gene therapies to treat patients with sickle cell disease
Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an innovative advancement in the field of gene therapy. (Source: World Pharma News)
Source: World Pharma News - December 8, 2023 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
Bayer and Salus Optima partner on AI-enabled healthy aging journey
Salus Optima, a leading provider in AI-enabled digital health and wellness solutions, and the Consumer Health division of Bayer have launched a strategic partnership to empower people on their healthy aging journey. The partnership elevates the shared aspiration of both companies to transform self-care by offering precision health solutions to enable consumers to better understand and make informed decisions about their own personal health and lifestyle choices. (Source: World Pharma News)
Source: World Pharma News - December 7, 2023 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
The risk of cardiovascular disease can be reduced by eating more oily fish
People with close relatives who have suffered from cardiovascular disease may benefit from eating more oily fish. This is according to a new study led by researchers from Karolinska Institutet, published in the journal Circulation.
Oily fish such as salmon, mackerel, herring and sardines contain the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). (Source: World Pharma News)
Source: World Pharma News - December 6, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
New technique efficiently offers insight into gene regulation
Researchers from the group of Jop Kind developed a new technique called MAbID. This allows them to simultaneously study different mechanisms of gene regulation, which plays a major role in development and disease. MAbID offers new insights into how these mechanisms work together or against each other. The results were published in Nature Methods on the 4th of December. (Source: World Pharma News)
Source: World Pharma News - December 5, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Pfizer announces topline Phase 2b results of oral GLP-1R agonist, danuglipron, in adults with obesity
Pfizer Inc. (NYSE: PFE) announced topline data from the Phase 2b clinical trial (NCT04707313) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes. The study met its primary endpoint demonstrating statistically significant change in body weight from baseline. (Source: World Pharma News)
Source: World Pharma News - December 4, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
A patch of protection against Zika virus
A simple-to-apply, needle-free vaccine patch is being developed to protect people from the potentially deadly mosquito-borne Zika virus.
A prototype using The University of Queensland-developed and Vaxxas-commercialised high-density microarray patch (HD-MAP) has delivered a University of Adelaide-developed vaccine and elicited an effective immune response to Zika virus in mice. (Source: World Pharma News)
Source: World Pharma News - December 1, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Scientists uncover how fermented-food bacteria can guard against depression, anxiety
University of Virginia School of Medicine researchers have discovered how Lactobacillus, a bacterium found in fermented foods and yogurt, helps the body manage stress and may help prevent depression and anxiety. The findings open the door to new therapies to treat anxiety, depression and other mental-health conditions.
The new research from UVA's Alban Gaultier, Ph.D., and collaborators is notable because it pinpoints the role of Lactobacillus, separating it out from all the other microorganisms that naturally live in and on our bodies. (Source: World Pharma News)
Source: World Pharma News - November 30, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Bayer and Hurdle launch precision health strategic partnership
Hurdle, a pioneer in diagnostic testing, and the Consumer Health division of Bayer have launched a strategic partnership to advance consumer innovations in the emerging area of healthy aging. The partnership is designed to enhance the companies' shared ambition to transform self-care through personalized solutions. (Source: World Pharma News)
Source: World Pharma News - November 29, 2023 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
FDA approves first therapy for rare type of non-cancerous tumors
The U.S. Food and Drug Administration approved Ogsiveo (nirogacestat) tablets for adult patients with progressing desmoid tumors who require systemic treatment. Ogsiveo is the first drug to be approved for the treatment of patients with desmoid tumors, a rare subtype of soft tissue sarcomas. (Source: World Pharma News)
Source: World Pharma News - November 28, 2023 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
AI may spare breast cancer patients unnecessary treatments
A new AI (Artificial Intelligence) tool may make it possible to spare breast cancer patients unnecessary chemotherapy treatments by using a more precise method of predicting their outcomes, reports a new Northwestern Medicine study.
AI evaluations of patient tissues were better at predicting the future course of a patient’s disease than evaluations performed by expert pathologists. (Source: World Pharma News)
Source: World Pharma News - November 27, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Lidocaine may be able to kill certain cancer cells by activating bitter taste receptors
Lidocaine - often used as numbing agent for outpatient medical procedures - activates certain bitter taste receptors through two unique mechanisms that result in cancer cell death, according to researchers from the Perelman School of Medicine at the University of Pennsylvania. Their findings, published in Cell Reports, pave the way for a clinical trial to test the addition of lidocaine to the standard of care therapy for patients with head and neck cancers. (Source: World Pharma News)
Source: World Pharma News - November 24, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Bayer invests 130 million EUR in new production facility for innovative parenteral products
Bayer has added a brand new manufacturing facility to its global supply chain network. The new production plant was inaugurated today at the company's global pharmaceutical headquarters in Berlin, Germany. The facility features state-of-the-art technology, innovative production, and automated processes. (Source: World Pharma News)
Source: World Pharma News - November 23, 2023 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news
Skin bacteria can save lives
Infections with antibiotic-resistant bacteria are a growing global problem. Part of the solution may lie in copying the bacteria's own weapons. The research environment in Tromsø has found a new bacteriocin, in a very common skin bacterium. Bacteriocin inhibits the growth of antibiotic-resistant bacteria that are often the cause of disease and can be difficult to treat. (Source: World Pharma News)
Source: World Pharma News - November 22, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Pfizer and Astellas & #039; XTANDI ® approved by U.S. FDA in earlier prostate cancer treatment setting
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Pfizer Inc. (NYSE: PFE) announced that the companies received an approval by the U.S. Food and Drug Administration (FDA) of a supplemental New Drug Application for XTANDI® (enzalutamide), following FDA expedited development and review programs (Priority Review designation, Fast Track designation, Real-time Oncology Review), based on results from the Phase 3 EMBARK trial. (Source: World Pharma News)
Source: World Pharma News - November 21, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
Potential therapeutic target found to combat tuberculosis, a disrupted NAD(H) homeostasis
It has been uncertain how Mycobacterium tuberculosis deflects the immune response in humans, though evidence has pointed to host immunometabolism - the intrinsic link between metabolism in immune cells and their immune function. The pathogen M. tuberculosis is known to disrupt a metabolic pathway called glycolysis in infected myeloid cells, which include macrophages, through an unclear mechanism. (Source: World Pharma News)
Source: World Pharma News - November 20, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
